top of page

FDA grants rare pediatric disease designation to Summit Therapeutics’ DMD drug

Summit Therapeutics has received second drug designation from the US Food and Drug Adminstration for ezutromid, a treatment for Duchenne Muscular Dystrophy (DMD).

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page